

1 SUPPLEMENTARY INFORMATION FOR:

2
3 **c-di-AMP hydrolysis by the phosphodiesterase AtaC**
4 **promotes differentiation of multicellular bacteria**
5

6 **Andreas Latoscha, David Jan Drexler, Mahmoud M. Al-Bassam, Adrian M. Bandera,**
7 **Volkhard Kaever, Kim C. Findlay, Gregor Witte* and Natalia Tschowri***

8 * Corresponding author: natalia.tschowri@hu-berlin.de

9 * Correspondence may also be addressed to: witte@genzentrum.lmu.de

10
11 **This PDF file includes:**

- 12 • Extended Experimental Procedures
- 13 • Table S1
- 14 • Figures S1 to S7
- 15 • Supplementary References

16
17 **EXTENDED EXPERIMENTAL PROCEDURES**

18 **Bacterial strains and growth conditions**

19 All strains used in this study are listed in Table S1. *Escherichia coli* strains were grown in LB
20 medium under aerobic conditions at 37 °C. If required, LB was supplemented with 100 µg/ml
21 ampicillin (Amp), 50 µg/ml kanamycin (Kan), 50 µg/ml apramycin (Apr) and/or 15 µg/ml
22 chloramphenicol (Cam). If hygromycin B (Hyg) was used, LB agar was replaced by Nutrient
23 Agar (NA; Roth) and LB was substituted by LBon (LB without salt) with addition of 16 µg/ml
24 and 22 µg/ml Hyg, respectively. *S. venezuelae* strains (Table S1) were grown aerobically at 30
25 °C in liquid Maltose-Yeast Extract-Malt Extract (MYM) medium (1) supplemented with trace
26 element solution (2) or on MYM agar. For growth analysis, 50 ml MYM were inoculated with
27 spores at a final concentration of 10⁶ CFU/ml and OD was measured at 578 nm. To study
28 development, 12 µl of 10⁵ CFU/µl *S. venezuelae* spores were spread as patches on MYM agar
29 and bacteria were photographed using a Canon EOS 1300D (W) camera after 4 days of growth
30 at 30 °C. For osmopressure experiments, 10 µl of serially diluted of *S. venezuelae* spores (10¹ to

31 10^4 CFU/ μ l) were dropped on NA medium with or without 0.5 M NaCl, respectively. Plates
32 were incubated at 30 °C and pictures were taken using a Canon EOS 1300D (W) camera. For
33 *in vivo* interaction studies using Bacterial Adenylate Cyclase Two-Hybrid (BACTH) assays
34 three corresponding single transformants of *E. coli* W3110 Δ *cya* were suspended in 1 ml of
35 sterile phosphate buffered saline (PBS) and 3 μ l of the resulting suspension was spotted on a
36 plate containing MacConkey Base Agar (Difco) supplemented with Amp (100 μ g/ml), Kan (50
37 μ g/ml) and maltose (1%). The plate was photographed using a Canon EOS 1300D (W) camera
38 after growth at 26 °C for 24 h.

39 **Generation and complementation of *S. venezuelae* c-di-AMP mutants**

40 Oligonucleotides and bacterial strains used for mutagenesis are listed Table S1.

41 *Generation of vnz_27310 (ataC) deletion mutant and phage transduction.* The *ataC*
42 deletion was conducted using a modified Redirect PCR targeting protocol (3, 4). *E. coli*
43 BW25113/pIJ790 cells induced for λ Red mediated recombination and containing cosmid
44 PI1_F15 (with *ataC*) were transformed with PCR amplified *aac(3)IV-oriT (apr-oriT)* cassette
45 extended with regions homologous to the *ataC* locus. After growth of transformants in presence
46 of apramycin only, cosmids were isolated and re-transformed into *E. coli* W3110 with selection
47 for Apr resistance. Correct integration of the Apr resistance cassette was verified by PCR using
48 test primers annealing to the *ataC* flanking region (Table S1). PI1_F15 *ataC::apr* was
49 transformed into strain ET12567/pUZ8002 and conjugated into wild type *S. venezuelae*.
50 Bacteria were plated on SFM agar, incubated overnight at room temperature (RT), overlaid
51 with 20 μ l of 25 mg/ml nalidixic acid (Nal) and of 50 mg/ml Apr in 2 ml ddH₂O and incubated
52 at 30 °C. *S. venezuelae* colonies were selected on NA containing Apr and Nal to remove *E. coli*.
53 Kan^S and Apr^R mutants were confirmed by PCR.

54 The *ataC::apr* allele was transduced into a new wild type background via SV1 phage
55 using a modified protocol from (5). Briefly, SV1 wild type phages were diluted and mixed with
56 *S. venezuelae* Δ *ataC* spores. After overnight incubation at 30 °C, plates were soaked with LB
57 at RT and phages were gathered and filtered using a 0.45 μ m filter. 100 μ l phages containing
58 the *ataC::apr* allele were plated with wild type spores on MYM agar and incubated overnight
59 at RT. For selection of desired transductants, plates were overlaid with 20 μ l 50 mg/ml Apr in
60 2 ml ddH₂O. The *ataC* deletion was confirmed by PCR.

61 *Generation of disA deletion mutant.* The *disA* mutant was generated by transduction of
62 the *disA::apr* allele (6) into the *S. venezuelae* wild type using SV1 phage.

63 *Generation of disA_{D86A} point mutation.* The point mutation was introduced using a
64 combination of modified Redirect PCR targeting and single stranded DNA recombineering
65 protocols as described in (7). The Kan resistance cassette in cosmid SV-4-B12 (containing *disA*)
66 was exchanged with *apr-oriT* extended with homologous regions to *neo*. The resulting cosmid
67 was used to generate the *E. coli* strain HME68/SV-4-B12 *neo::apr-oriT* which was induced for
68 λ Red recombination and electroporated with the mutagenic oligonucleotide
69 *disA_D86Achr_rev* and oligo100 (8) and plated on MacConkey agar containing 1% galactose
70 and Apr. Red, Apr^R clones were analyzed for the *disA::disA_{D86A}* allele by PCR using a primer
71 pair specific for the D86A mutation and sequencing. Purified cosmid was electroporated into
72 ET12567/pUZ8002 and conjugated into wild type *S. venezuelae*. Single colonies were selected
73 on NA medium containing Apr and Nal followed by growth on NA without antibiotics to
74 achieve loss of the cosmid. Colonies sensitive to Apr were verified for the *disA* D86A mutation
75 by sequencing.

76 *Complementation of the deletion mutants.* To complement the *disA* deletion, a DNA
77 fragment containing the wild type allele with 528 bp upstream of the start codon (including
78 *disA* promoter) was cloned into pIJ10770 or its derivative p3xFLAG which allow integration
79 at the *attB_{ΦBT1}* site in the *S. venezuelae* chromosome. pIJ10770-*disA* and p3xFLAG-*disA*,
80 respectively, were conjugated into *disA::apr* using *E. coli* ET12567/pUZ8002. After selection
81 on NA medium containing Nal and Hyg, Hyg^R colonies were grown on MYM agar for spore
82 stock generation.

83 The complementation of the *ataC* deletion mutant with the wild type allele was
84 conducted similarly. Here, using an overlap PCR, a DNA fragment corresponding to 200 bp
85 upstream of the start codon of *vnz_27305* was fused to full length *ataC* resulting in the construct
86 *vnz_27305prom-ataC*. The fragment was cloned into pIJ10770 resulting in the plasmid
87 pSVAl11 and introduced into the Δ *ataC* chromosome as described above. For
88 complementation of Δ *ataC* with the D269N allele, pSVAl11 was used as template in a
89 backbone PCR to amplify a circular construct with the primers D269N_backbone_f and
90 D269N_backbone_r. The plasmid pIJ10770-*vnz_27305prom-ataC_{D269N}* was generated, the
91 mutation confirmed by sequencing and conjugated into Δ *ataC* as described above.

92 **Construction of plasmids**

93 Oligonucleotides used for cloning are listed in Table S1. *disA*, *vnz_31010*, *ataC* and *vnz_28055*
94 were amplified from *S. venezuelae* genomic DNA (gDNA). D86A point mutation in *disA* was

95 introduced by following the four-primer/two-step PCR protocol (9). PCR products of all
96 constructs were cloned into the pET15b vector. The *ataC*_{D269N} construct was obtained using
97 quick change site directed mutagenesis using the pET15b-*ataC* plasmid as a template. Codon
98 optimized *ataC*_{Spm} was synthesized *de novo* and cloned into pET15b via the NdeI and BamHI
99 restriction sites by GenScript.

100 Full-length *cpeA* (*vnz_28055*) and *cpeB* (*vnz_28050*) excluding the respective stop codons were
101 cloned into pUT18 and pKNT25 (Euromedex). The resulting constructs carry in-frame fusions
102 of the sequences encoding the T18 and T25 fragments of *cyaA* from *Bordetella pertussis* to the
103 3' end of *cpeA* and *cpeB*, respectively. Expression of the fused genes is under control of the *lac*
104 promoter(*lacP*). To introduce *disA-FLAG* into pUT18-*vnz_28055*, the gene was PCR-amplified
105 from the plasmid p3xFLAG-*disA* with introduction of homologous regions to *lacP* and pUT18-
106 *vnz_28055*. Additionally, *lacP* was amplified from pUT18 with homologous regions to pUT18-
107 *vnz_28055* and *disA-FLAG*. pUT18-*vnz_28055*, *lacP* and *disA-FLAG* were combined via
108 Gibson Assembly (New England BioLabs) to generate the plasmid pUT18-*vnz_28055-disA-*
109 *FLAG*. The resulting plasmid encodes the *cpeA-T18* fusion as well as *lacP*-controlled *disA-*
110 *FLAG* downstream of the T18 fragment. A quick change site directed mutagenesis using
111 pUT18-*vnz_28055-disA-FLAG* and primers *disA_D86A_fwd* and *disA_D86A_rev* was
112 performed to generate pUT18-*vnz_28055-disA_{D86A}-FLAG*.

113 **Protein overexpression and purification**

114 pET15b constructs were transformed into *E. coli* BL21 (DE3) pLysS. Rosetta (DE3) pET28-
115 *disA_{Bsu}* was directly used for overexpression. LB containing Amp and Cam (and 0.2% glucose
116 in case of PDEs) was inoculated 1:100 with overnight cultures and grown with shaking at 37
117 °C. For DisA_{Bsu} overexpression, Amp was replaced with 25 µg/ml Kan. Cultures were induced
118 with a final concentration of 0.1-0.2 mM IPTG at OD₅₇₈ between 0.5 and 0.7; cultures for PDE
119 overexpression were supplemented with 0.35 mM MnCl₂ (10). Proteins were overexpressed
120 overnight at 16 °C and shaking. Subsequently, cultures were pelleted and lysed using a
121 FrenchPress. Strains expressing DisA variants and 6xHis-CpeA were lysed in DisA lysis buffer
122 (20 mM Tris HCl, pH 8; 300 mM NaCl, 10% glycerol, 20 mM imidazole; 0.05% Triton X-100;
123 0.5 mM DTT; 5 mM MgCl₂) supplemented with cComplete protease inhibitor cocktail tablets,
124 EDTA-free (Roche). Strains expressing 6xHis-Vnz_31010, 6xHis-AtaC and 6xHis-AtaC_{Spm}
125 were lysed in PDE lysis buffer containing cComplete protease inhibitor cocktail tablets, EDTA-
126 free (similar to DisA lysis buffer but Tris HCl, pH 8 replaced by 20 mM Tris HCl 7.5; MgCl₂

127 replaced by 10 mM MnCl₂). Clarified lysate supernatants of 6xHis-tagged proteins were loaded
128 on 0.5-1 ml 50% Ni-NTA SuperFlow (iba) overnight at 4 °C. Then, the matrix was washed with
129 respective lysis buffers. DisA protein variants and 6xHis-CpeA were eluted with the following
130 buffer: 50 mM Tris HCl, pH 8; 300 mM NaCl; 10% glycerol; 250 mM imidazole; 0.5 mM
131 DTT; 5 mM MgCl₂. The PDE elution buffer was similar to DisA elution buffer but containing
132 50 mM Tris HCl, 7.5 instead of Tris HCl, pH 8 and 10 mM MnCl₂ instead of MgCl₂. Fractions
133 containing eluted proteins (identified by Coomassie staining of 12% polyacrylamide gels) were
134 pooled. Eluates of DisA variants and 6xHis-CpeA were dialyzed twice in DisA cyclase buffer
135 (25 mM Tris HCl, pH 8; 250 mM NaCl, 10 mM MgCl₂, 5 mM β-mercaptoethanol, 10% glycerol
136 (modified from (11), and tested PDEs were dialyzed twice in PDE buffer with 5-10% glycerol
137 (20 mM Tris HCl, pH 7.5; 50 mM NaCl; 10 mM MnCl₂ (modified from (10) at 4 °C under
138 stirring. Dialyzed proteins were stored at -20 °C until further use in diadenylate cyclase (DAC),
139 differential radial capillary action of ligand (DRaCALA) or phosphodiesterase (PDE) assays.
140 For characterization of biophysical properties of 6xHis-AtaC and 6xHis-AtaC_{D269N}, Rosetta
141 (DE3) cell pellets containing pET15b-*ataC* and pET15b-*ataC*_{D269N} constructs, respectively,
142 were resuspended in buffer A (20 mM HEPES, 300 mM NaCl, 20 mM imidazole, 10% glycerol,
143 0.5 mM MnCl₂, pH 7.5) and lysed by sonication. After centrifugation, clear supernatant was
144 loaded on Ni-NTA columns. The columns were washed with buffer A and proteins were eluted
145 with buffer B (20 mM HEPES, 100 mM NaCl, 250 mM imidazole, 10% glycerol, 0.5 mM
146 MnCl₂, pH 7.5). Protein elution fractions were concentrated prior to size exclusion
147 chromatography on a HiLoad Superdex 200 column (GE Healthcare) equilibrated with buffer
148 C (20 mM HEPES, 100 mM NaCl, 0.5 mM MnCl₂, pH 7.5). Pure proteins were concentrated,
149 flash frozen in liquid nitrogen and stored at -80 °C.

150 **c-di-AMP extraction and quantification**

151 The nucleotide extraction protocol from (12) was adapted to *Streptomyces*. Wild type, Δ *disA*
152 and Δ *ataC* strains were grown in 100 ml MYM. Beginning with 10 h, 5 ml samples for c-di-
153 AMP extraction and two 1 ml samples for protein determination were taken every 2 h. c-di-
154 AMP samples were centrifuged at 4000 rpm and 4 °C for 15 min using a swing rotor (Heraeus
155 Megafuge 16R, Thermo Scientific), frozen in liquid nitrogen and stored at -80 °C. Protein
156 samples were centrifuged at max. speed and stored at -20 °C.

157 For c-di-AMP extraction, samples were suspended in 800 μl Extraction mixture II
158 (acetonitrile/methanol/water [2:2:1]), transferred into 2 ml screw cap tubes prefilled with 0.1

159 mm silica beads (Biozym), shock frozen for 15 s in liquid nitrogen and heated for 10 min at 95
160 °C. After cooling on ice, samples were disrupted using the BeadBlaster at 4 °C with 2 cycles at
161 6 m/s for 45 s and 2 min interval. Samples were cooled for 15 min on ice and centrifuged at
162 max. speed and 4 °C for 15 min. Supernatants were transferred into a 2 ml reaction tubes.
163 Remaining pellets were suspended in 600 µl Extraction mixture I (acetonitrile/methanol [1:1]),
164 pulsed two times for 30 s at 6 m/s with a 60 s interval, incubated on ice and centrifuged as
165 above. The extraction with 600 µl Extraction mixture I was repeated once. All supernatants (~2
166 ml) were combined and stored for protein precipitation for two days at -20 °C. Precipitated
167 proteins were removed by centrifugation and the precipitation step was repeated. Finally,
168 samples were air dried in a SpeedVac Plus SC110A connected to Refrigerated Vapor Trap
169 RVT100 (Thermo Scientific) at low temperature settings and analyzed using LC-MS/MS as
170 described in (12).

171 Samples for protein quantification were suspended in 800 µl 0.1 M NaOH, transferred into 2
172 ml screw cap tubes prefilled with 0.1 mm silica beads (Biozym) and heated for 10 min at 98
173 °C. Cell lysis was performed in BeatBlaster with 2 pulses for 30 s at 6 m/s and an interval of 2
174 min. Lysates were centrifuged at max. speed and 4 °C for 15 min. Supernatant was saved and
175 the extraction step was repeated. Supernatants were combined and protein concentration was
176 determined via Bradford using Roti-Quant.

177 For normalization of c-di-AMP concentration to the protein amount, following formula was
178 used:

$$179 \frac{c-di-AMP [nM] \cdot 200 \mu l}{cV [ml] \cdot c590 \left[\frac{\mu g}{ml \text{ cells}} \right]} = \frac{c-di-AMP [pmol]}{protein [mg]}$$

180 **Isothermal Titration Calorimetry**

181 ITC experiments were performed using a Malvern PEAQ-ITC system with 21 µM protein in
182 ITC buffer (20 mM HEPES, pH = 7.5; 100 mM NaCl) in the cell. The respective nucleotides
183 (210 µM) were titrated into the cell by 19 injections of 2 µl, spaced 150 s apart, at 25 °C. The
184 data was analyzed using the MicroCal PEAQ-ITC analysis software provided with the
185 instrument. All titrations were repeated to confirm robustness of the assay.

186 **Size-exclusion chromatography (SEC) coupled static light scattering and analytical SEC**

187 Determination of the molecular weight of AtaC was performed using a 24 ml Superdex S200
188 increase size-exclusion column (GE Healthcare Lifesciences) connected to a multi-angle laser
189 light scattering and a refractive index monitor (WYATT miniDAWN TREOS, WYATT

190 Outilab T-rEX). Data were analyzed using the ASTRA software package provided with the
191 instrument (Wyatt). Static light scattering data of CpeA samples were obtained using the same
192 column connected to a ÄKTAmicro system (GE Healthcare Lifesciences) equipped with
193 Malvern/Viscotek RI and RALS (right-angle laser scattering) devices (as described in (13)).
194 Data evaluation was done using the OmniSEC software package. Analytical SEC runs were
195 performed on an ÄKTAmicro system and a 24 ml Superdex S75 column.

196 **Surface plasmon resonance**

197 SPR experiments were conducted using a Biacore X100+ (GE Healthcare Lifesciences) at 25
198 °C. 2'-Biotin-16-c-di-AMP (BioLog) was immobilized on a SA-chip (GE Healthcare
199 Lifesciences) in HPS-EP+ buffer (10 mM Hepes pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05%
200 v/v Surfactant P20) to a final RU of 150. The analyte (CpeA) was injected at concentrations of
201 1-100 µM (dimer concentration) in HPS-EP+ with a contact time of 120 s. Between every
202 injection the chip was regenerated by 30 s injections of 6 M Urea and 2 M NaCl. The resulting
203 sensorgrams were analysed by the Biacore evaluation software. Steady state report point for
204 data evaluation was chosen 5 seconds prior to injection stop.

205 **Heat resistance assay**

206 Spore heat resistance was assessed as previously described (5). $\sim 10^9$ CFU/ml spores were
207 shocked at 50 °C for 1 h. Spores were serially diluted for colony forming unit (CFU)
208 determination. The ratio of CFU after heat shock versus CFU before the heat shock was used
209 to calculate the survival rate for each strain.

210 **Bioinformatic characterization of AtaC and its abundance in prokaryotes**

211 A local PATRIC database was installed and used to determine the conservation of AtaC
212 (PGF_00172869) across prokaryotes (Dataset S1). Duplicated entries with identical genome
213 were removed (177 in total), but keeping the first entry. An in-house python script was used to
214 extract taxonomic information for each of the AtaC homologues. Specifically, the accession
215 number of each species was used to access NCBI taxonomy and the taxonomic information was
216 integrated with the original PATRIC table. Only phyla with more than 5 genomes were kept,
217 and entries with no taxonomic information were excluded from the analysis.

218

219 **Table S1. Strains, plasmids and oligonucleotides used in this study**

	Genotype or comments	Source or reference
Strains		
<i>S. venezuelae</i>		
NRRL B-65442	Wild type	(NCBI Reference Sequence: NZ_CP018074.1)
<i>disA::apr</i>	ATCC 10712 <i>SVEN_3211::aac(3)IV</i> ; Apr ^R	(6)
SVAL5	Δ <i>disA::apr</i> , <i>attB</i> _{ΦBT1} ::p3xFLAG- <i>disA</i> ; Apr ^R , Hyg ^R	This study
SVAL8	<i>disA::disA</i> _{D86A}	This study
SVAL19	Δ <i>disA</i> (SV1-transduction); Apr ^R	This study
SVAL20	Δ <i>vnz_27310::apr</i> (Redirect); Apr ^R	This study
SVAL22	Δ <i>ataC::apr</i> (SV1-transduction from SVAL20); Apr ^R	This study
SVAL24	Δ <i>disA::apr</i> , <i>attB</i> _{ΦBT1} ::pIJ10770- <i>disA</i> ; Apr ^R , Hyg ^R	This study
SVAL26	Δ <i>ataC::apr</i> , <i>attB</i> _{ΦBT1} ::pIJ10770- <i>vnz_27305prom-ataC</i> ; Apr ^R , Hyg ^R	This study
SVAL27	Δ <i>ataC::apr</i> , <i>attB</i> _{ΦBT1} ::pIJ10770- <i>vnz_27305prom-ataC</i> _{D269N} ; Apr ^R , Hyg ^R	This study
<i>E. coli</i>		
W3110	K-12 derivative; <i>F</i> ⁻ , λ ⁻ , <i>rpoS</i> (<i>Am</i>), <i>rph-1</i> , <i>Inv</i> (<i>rrnD-rrnE</i>)	(14)
W3110 Δ <i>cyd</i>	W3110 derivative with deleted adenylate cyclase	(15)
ET12567/pUZ8002	<i>dam</i> , <i>dcm</i> , <i>hsd</i> ; Kan ^R , Cm ^R	(16)
BW25113/pIJ790	(Δ (<i>araD-araB</i>)567, Δ <i>lacZ</i> 4787(:: <i>rrnB-4</i>), <i>lacI</i> p-4000(<i>lacI</i> ^Q), λ ⁻ , <i>rpoS</i> 369(<i>Am</i>), <i>rph-1</i> , Δ (<i>rhaD-rhaB</i>)568, <i>hsdR</i> 514; Cm ^R	(17)

BL21 (DE3) pLysS	F ⁻ <i>ompT hsdS</i> (rB ⁻ mB ⁻) <i>gal dcm</i> λ(DE3), Cm ^R	Promega
HME68	W3110 Δ(<i>argF-lac</i>)U169 <i>galKtyr145UAG</i> <i>mutS</i> <> <i>cat</i>	(18)
Rosetta (DE3) pET28- <i>disA</i> _{Bsu}	Overexpression of <i>Bacillus subtilis</i> DisA; Kan ^R , Cm ^R	(19)
Rosetta 2 (DE3)	F ⁻ <i>ompT hsdS</i> _{B(rB⁻ mB⁻)} <i>gal dcm</i> (DE3) pRARE2 (Cm ^R)	Novagen
Plasmids		
pIJ773	Plasmid template for amplification of the <i>apr-oriT</i> cassette for 'Redirect' PCR-targeting; Apr ^R	(3)
pIJ790	Modified λRED recombination plasmid [<i>oriR101</i>] [<i>repA101</i> (ts)] <i>araBp-gam-be-exo</i> ; Cm ^R	(3)
pIJ10770	pMS82 derivative; Hyg ^R	(20)
pUZ8002	RP4 derivative with defective <i>oriT</i> ; Kan ^R	(16)
p3xFLAG	pIJ10770 derivative containing <i>3xFLAG</i> sequence downstream of MCS; Hyg ^R	(21)
pGEX_6P_1	T7 expression vector (modified MCS); Amp ^R	GE Healthcare
pET15b	T7 expression vector; Amp ^R	Novagen
pKNT25	Low copy vector encoding the T25 fragment of <i>Bordetella pertussis cyaA</i> downstream of the MCS; Kan ^R	Euromedex
pUT18	High copy vector encoding the T18 fragment of <i>B.</i> <i>pertussis cyaA</i> downstream of the MCS; Amp ^R	Euromedex
pECAL1	pET15b- <i>disA</i> ; Amp ^R	This study
pECAL4	pET15b- <i>disA</i> _{D86A} ; Amp ^R	This study
pECAL12	pET15b- <i>ataC</i> ; Amp ^R	This study
pECAL13	pET15b- <i>vnz_31010</i> ; Amp ^R	This study

pECAL16	pET15b- <i>ataC_{Spn}</i> ; Amp ^R	This study
pECAL17	pET15b- <i>vnz_28055 (cpeA)</i> ; Amp ^R	This study
pECAL18	pKNT25- <i>vnz_28050 (cpeB)</i> ; Kan ^R	This study
pECAL19	pUT18- <i>vnz_28055 (cpeA)</i> ; Amp ^R	This study
pECAL20	pUT18- <i>vnz_28055-disA-FLAG</i> ; Amp ^R	This study
pECAL21	pUT18- <i>vnz_28055-disA_{D86A}-FLAG</i> ; Amp ^R	This study
pSVAL6	pIJ10770- <i>disA</i> ; Hyg ^R	This study
pSVAL11	pIJ10770- <i>vnz_27305prom-ataC</i> (200 bp upstream of <i>vnz_27305</i> start codon fused to <i>ataC</i>); Hyg ^R	This study
pSVAL12	pIJ10770- <i>vnz_27305prom-ataC_{D269N}</i> (pSVAL11 derivative); Hyg ^R	This study
pSVNT-10	p3xFLAG- <i>disA</i> ; Hyg ^R	This study
pDD29	pET15b- <i>ataC_{D269N}</i> (pECAL12 derivative); Amp ^R	This study

220 Underlined nucleotides indicate restriction sites, nucleotides in bold represent introduced mutations and
221 nucleotides in italics indicate sequences overlapping to other genes


Oligonucleotide	Sequence
Oligonucleotides used for generation of the chromosomal <i>disA</i> D86A point mutation, PCR verification and sequencing	
disA_D86Achr_rev	TCTTGGTGATGTCCTTGTGCGAGGACGAGCGCGCCCGCGAGCTTGAC AGCTCCCGCAGCCGCGTGGCGGC
disA_D86A_check_fwd	GGAGCTGTGCAAGCTCGCG
disA_fwd_NdeI	TATCATATGGTGGCAGCCAAGGAC
disA_rev_XhoI	TATCTCGAGCTAGACGTACCGCTCAAG
Oligonucleotides used for verification of <i>disA</i> deletion	
disA_test_f	GTGGTTCACTCACGCCGCATGAACGGTTC

disA_test_r	GGCACGTACCTGGTGGAGGCCGAAGGTG
Oligonucleotides used for complementation of <i>disA</i> deletion with <i>disA-3xFLAG</i>	
3142_NdeI-for	GCTGCATATGGGCCGGCGGGTCCG
3142_XhoI-rev	GCAGCCTCGAGGACGTACCGCTCAAGGATC
Oligonucleotides used for complementation of <i>disA</i> deletion with wild type <i>disA</i>	
3142_NdeI-for	GCTGCATATGGGCCGGCGGGTCCG
disA_rev_XhoI	TATCTCGAGCTAGACGTACCGCTCAAG
Oligonucleotides used for <i>vnz_27310 (ataC)</i> deletion and PCR verification	
27310_fwd_Apra	CGAAGCGATCGCGGCCACCGCCGCGCCCACCCGCTGATGATTCCGGG <i>GATCCGTCGACC</i>
27310_rev_Apra	GGTCGTGGGGGGGAGGAGACGGGTGAGGAGTGGGCTCATGTAGGC <i>TGGAGCTGCTTC</i>
27310_test_f	ACACCGTGCGGCAGACCC
27310_test_r	TTCCCGCAGTCCATGGTTCC
Oligonucleotides used for complementation of <i>ataC</i> deletion (sequences overlapping to putative promoter in italics)	
27305prom_f_NdeI	TATCATATGGGTGTCCCGGCTCGTCGAC
27305prom_r_OL_ataC	GCTGCACCATGGACTCCATCCTACGGGGCT
ataC_f_OL_27305prom	<i>GATGGAGTCCATGGTGCAGCCGACCGCCGT</i>
5409_rev_XhoI	TATACTCGAGTCAGGTGCGGACTTCGAG
Oligonucleotides used for generation of <i>pIJ10770-vnz_27305prom-ataC_{D269N}</i>	
D269N_backbone_f	CGGCGCTGTACGTCACGGCCAACCACGGCATGGTCGACAT
D269N_backbone_r	ATGTCGACCATGCCGTGGTTGGCCGTGACGTACAGCGCCG
Oligonucleotides used for generation of pET15b overexpression constructs	

disA_fwd_NdeI	TATCATATGGTGGCAGCCAAGGAC
disA_rev_XhoI	TATCTCGAGCTAGACGTACCGCTCAAG
disA_D86A_fwd	GCAAGCTCGCGGGCGCGCTC
disA_D86A_rev	GAGCGCGCCCCGCGAGCTTGC
5409_fwd_NdeI	TATCATATGATGGTGCAGCCGACCG
5409_rev_XhoI	TATACTCGAGTCAGGTGCGGACTTCGAG
6143_fwd_NdeI (for <i>vnz_31010</i>)	TATCATATGGTGATCGTCATCGCCCATGT
6143_rev_BamHI (for <i>vnz_31010</i>)	TATGGATCCTCAGACCGGCACGGTC
28055_fwd_NdeI	TAT CATATG GTGCCTGCTCCACGGATG
28055_rev_XhoI	TATA CTCGAG TCACTCCCGTCCGAGTATGG
Oligonucleotides used for generation of the pET15b-<i>ataC</i>_{D269N} construct	
DD60AtaC(D269N)_fwd	GTACGTCACGGCCAACCACGGCATGGTCGA
DD61AtaC(D269N)_rev	GGCCGTGACGTACAGCGCCGAGC
Oligonucleotides used for generation of the constructs for bacterial two hybrid interaction studies	
28050_NT25f_XbaI	TATCTAGACGTGCATTCCGCTCTGTTTCCT
28050_NT25r_KpnI	TATGGTACCCGCGCGCGGCCGGCCGGATCCT
28055_T18f_KpnI	TATGGTACCGCCTGCTCCACGGATGAGC
28055_T18r_EcoRI	TAGCAGAATTCTGACTCCCGTCCGAGTATGGAGG
T18RCKC_disAFLAG_f	<i>cgacaagtag</i> TATGGTGCCTCTCAGTAC
T18RCKC_lacp_r	<i>gtgccagctg</i> TTACTTAGTTATATCGATTGGC
lacp_T18RCKC_f	<i>aactaagtaa</i> CAGCTGGCAGACAGGTTTC
lacp_disAFLAG_r	<i>ccttgctgc</i> CATAGCTGTTTCCTGTGTGAAATTGTTATC

disAFLAG_lacp_f	<i>aacagctatg</i> GCAGCCAAGGACGGGGCA
disAFLAG_T18RCKC_r	<i>gtgcaccata</i> CTACTTGTCGTCATCGTCCTTGTAGTCG
T18RCKC_testFLAG_f	<i>gagcggacgttcgaagtct</i>
T18RCKC_testFLAG_r	<i>cggtcacagcttgctgtaa</i>

222



223
 224 **Figure S1. Loading controls for Western blot analysis of DisA-FLAG and AtaC**
 225 **expression patterns.**

226 (A) C-terminally FLAG-tagged *disA* was introduced using the integrative pIJ10770 vector into
 227 $\Delta disA$ strain and expressed under the control of its native promoter from the *attB* _{Φ BT1} integration
 228 site.


229 (B) Wild type *S. venezuelae* was used for AtaC analysis.

230 Strains were grown in liquid MYM at 30 °C and samples were taken every 2 hours after
 231 indicated time of growth (numbers above the lanes). *S. venezuelae* wild type and $\Delta ataC$
 232 samples harvested after 20 hours of growth served as negative controls in the relevant assays.
 233 Whole cell lysates were prepared as described in (21). 5 and 10 μ g of whole cell proteins were
 234 used for DisA-FLAG and AtaC detection, respectively. For each Western blot analysis, the
 235 proteins were separated on two SDS polyacrylamide gels that were run in parallel in SDS buffer
 236 at 50 mA for 40-50 min. One gel was stained with Coomassie and used as loading control
 237 (Figure S1A, B). The other gel was used for Western blotting and detection of DisA-FLAG
 238 with anti-FLAG as primary antibody (Sigma) (Figure 1C) or AtaC with anti-AtaC antiserum as
 239 primary antibody (generated by Pineda GmbH using purified 6xHis-AtaC) (Figure 4B).

240

241

242



243

244 **Figure S2. Hydrolysis activity of AtaC is specific for adenosine bases.**

245 (A) Ion-exchange chromatography run on a Resource Q column of the reaction products after
 246 1 h incubation from a 100 μ l reaction containing 100 nM AtaC + 250 μ M c-di-AMP.

247 (B) Michaelis-Menten kinetics of the reactions from 400 nM AtaC + c-di-AMP (62.5 – 2000
 248 μ M) and 100 nM AtaC + 5'-pApA (62.5 – 2000 μ M) after 1 h of incubation at 37 $^{\circ}$ C. c-di-
 249 AMP, $K_M = 285 \pm 32 \mu\text{M}$, $k_{\text{cat}} = 0.2 \text{ s}^{-1}$; 5'-pApA, $K_M = 698 \pm 32 \mu\text{M}$, $k_{\text{cat}} = 2.1 \text{ s}^{-1}$. Shown are
 250 mean values of $n=3$ independent experiments and standard deviation.

251 (C) Ion-exchange chromatography run on a Resource Q column of the reaction products after
 252 1 h incubation from a 100 μ l reaction containing 100 nM AtaC + 250 μ M c-di-GMP.


253 (D) Ion-exchange chromatography run on a Resource Q column of the reaction products after
 254 1 h incubation from a 100 μ l reaction containing 100 nM AtaC + 250 μ M c-di-AMP.

255 (E) Ion-exchange chromatography run on a Resource Q column of the reaction products after
 256 1 h incubation from a 100 μ l reaction containing 100 nM AtaC + 250 μ M 5'-pGpG.

257 (F) Ion-exchange chromatography run on a Resource Q column of the reaction products after 1
 258 h incubation from a 100 μ l reaction containing 100 nM AtaC + 250 μ M 5'-pApG.

259

260



261

262 **Figure S3. AtaC is a monomer in solution.**

263 (A) Molecular weight determination of AtaC by SEC coupled multi-angle laser light scattering.


264 The obtained molecular weight is 43.7 kDa and stable for the main protein peak at 25 ml.

265 (B) shows the relative scattering intensity of the sample during a size-exclusion coupled SAXS
 266 run at EMBL-P12 using a 24 ml Superdex increase S200 10/300 column (Intensity vs. frame
 267 No.). The respective estimated radius of gyration for each frame in the main peak is shown in
 268 red (right Y-axis).

269 (C) Measured SAXS curve of AtaC in 200 mM NaCl, 20 mM HEPES pH 7.5 and a theoretical
 270 scattering curve (red) of the model of AtaC using PhnA as template (obtained from
 271 HHpred/MODELLER (22), $\chi^2=3.6$).

272 (D) Guinier plot $\ln I(s)$ vs. s^2 (top part) of the averaged buffer corrected scattering data (from
 273 B) and the respective residuals of the linear regression ($R_G= 2.41 \pm 0.1\text{nm}$). The equally
 274 distributed errors of the linear regression (for $s \cdot R_G < 1.3$, Guinier approximation) indicates that
 275 the sample is not aggregating.

276




277

278 **Figure S4. AtaC_{D269N} does not cleave c-di-AMP and does not bind c-di-GMP.**

279 (A) Ion-exchange chromatography run on a Resource Q column of the reaction products after
 280 1 h incubation from a 100 μ l reaction containing 1 μ M AtaC_{D269N} + 250 μ M c-di-AMP.

281 (B) ITC measurement of 20 μ M AtaC titrated with 140 μ M c-di-GMP. No binding was
 282 detected.

283




284

285 **Figure S5. Viability of spores produced by c-di-AMP mutants and complementation of**
 286 **the $\Delta ataC$ and $\Delta disA$ strains with the wild type alleles.**

287 (A) Deletion or inactivation of c-di-AMP metabolizing enzymes has no impact on spore
 288 viability of the respective mutants. Spores ($\sim 10^9$ CFU/ml) were heat shocked for 1 h at 50 °C.
 289 Spores were serially diluted and colony forming units (CFU) were determined. The survival of
 290 each strain was assessed by the ratio CFU after the heat shock and CFU before the heat shock.
 291 Data are presented as the mean of CFU counts from at least three different dilutions \pm standard
 292 deviation and show representative data of three independent experiments.

293 (B) Upper panel: scanning electron micrographs show that expression of *ataC* from the *attB* _{Φ BT1}
 294 site under the control of the native promoter from pIJ10770 complemented the delayed
 295 developmental phenotype of the *ataC* mutant. Lower panel: Expression of *disA* from pIJ10770
 296 in the *disA* mutant did not alter the wild type phenotype of the mutant. For comparison see also
 297 Figure 5B in the main text. Cells were grown on MYM for 4 days at 30 °C.



299 **Figure S6. CpeA preferentially binds c-di-AMP in nanoDSF.**

300 nanoDSF thermal shift assays at a heating rate of 1.5 °C/min: concentration legend (left
301 panel), raw data ratio fluorescence (middle panel), raw data first derivative of ratio (right
302 panel).

303 (A) nanoDSF thermal shift assay of 20 μ M CpeA with different concentrations of c-di-AMP
304 (0 - 5 mM).

305 (B) nanoDSF thermal shift assay of 20 μ M CpeA with different concentrations of ATP (0 - 20
306 mM).


307 (C) nanoDSF thermal shift assay of 20 μ M CpeA with different concentrations of AMP (0.05
308 - 27.75 mM).

309 (D) nanoDSF thermal shift assay of 20 μ M CpeA with different concentrations of cAMP (0.2
310 - 6.25 mM).

311 (E) nanoDSF thermal shift assay of 20 μ M CpeA with different concentrations of 5'-pApA
312 (0.38 - 12.25 mM).

313 (F) nanoDSF thermal shift assay of 20 μ M CpeA with different concentrations of c-di-GMP
314 (0.29 - 9.25 mM).

315



316

317 **Figure S7. CpeA binding of c-di-AMP and CpeA *in vitro* properties.**

318 (A) left panel: SPR sensorgram of biotin-c-di-AMP immobilized on a SA-chip with injections

319 of 1-100 μM dimeric CpeA. Right panel: Binding curve fit of the steady state response units

320 for the titration of CpeA (dimer) and 2'-biotin-C₁₆-c-di-AMP (one-site binding model, $K_D =$

321 $37 \pm 2.9 \mu\text{M}$, $R^2=0.997$) determined by SPR at 25 °C.

322 (B) shows the (only) peak of a size-exclusion coupled light scattering experiment using a CpeA-

323 sample (5 mg/ml CpeA) on loaded onto a Superdex S200 increase 10/300 column equilibrated

324 in buffer 20 mM Tris HCl pH 8, 200 mM NaCl, 3% glycerol, 1 mM DTT and the respective
325 molecular weight curve (red) for the peak. The average molecular weight for the peak fraction
326 is $M_w^{SECRALS}=40.2$ kDa and stable for the whole peak region indicating that CpeA forms a
327 dimer in solution.

328 (C) shows analytical size exclusion runs of different concentrations of CpeA (injected 100 μ l
329 of a) 5 mg/ml, b) 0.5 mg/ml, c) 0.03 mg/ml, and d) 0.005 mg/ml) loaded on a Superdex S75
330 10/300 column. The dimer peak at $V_{elution}=10.8$ ml is stable for all concentrations indicating no
331 detectable dissociation in this concentration regime.

332 (D) shows the small-angle X-ray scattering curve of a 1.6 mg/ml CpeA sample (in 200 mM
333 NaCl, 30 mM NaP_i pH 6.5, 5% v/v glycerol),

334 (E) the respective Guinier Plot $\ln(I)$ vs s^2 and residuals of the linear regression region (red dots).
335 The molecular weight of CpeA determined from SAXS is $M_w=39.1$ kDa with a radius of
336 gyration of $R_G=2.7$ nm (extrapolated from a concentration series to $c=0$ mg/ml, the R_G for the
337 curve shown in (C+D) is $R_G^{c=1.6\text{mg/ml}}=2.78$ nm).

338

339 SUPPLEMENTARY REFERENCES

- 340 1. C. Stuttard, Temperate phages of *Streptomyces venezuelae*: lysogeny and host
341 specificity shown by phages SV1 and SV2. *Microbiology* **128**, 115-121 (1982).
- 342 2. T. Kieser, M. J. Bibb, M. J. Buttner, K. F. Chater, D. A. Hopwood, *Practical*
343 *Streptomyces Genetics*. (The John Innes Foundation, Norwich, 2000).
- 344 3. B. Gust, G. L. Challis, K. Fowler, T. Kieser, K. F. Chater, PCR-targeted *Streptomyces*
345 gene replacement identifies a protein domain needed for biosynthesis of the
346 sesquiterpene soil odor geosmin. *Proceedings of the National Academy of Sciences of*
347 *the United States of America* **100**, 1541-1546 (2003).
- 348 4. B. Gust *et al.*, Lambda red-mediated genetic manipulation of antibiotic-producing
349 *Streptomyces*. *Advances in applied microbiology* **54**, 107-128 (2004).
- 350 5. N. Tschowri *et al.*, Tetrameric c-di-GMP mediates effective transcription factor
351 dimerization to control *Streptomyces* development. *Cell* **158**, 1136-1147 (2014).
- 352 6. R. J. St-Onge *et al.*, Nucleotide Second Messenger-Mediated Regulation of a Muralytic
353 Enzyme in *Streptomyces*. *Molecular microbiology* **96**, 779-795 (2015).
- 354 7. M. A. Schumacher *et al.*, The *Streptomyces* master regulator BldD binds c-di-GMP
355 sequentially to create a functional BldD₂-(c-di-GMP)₄ complex. *Nucleic acids research*
356 **45**, 6923-6933 (2017).
- 357 8. N. Costantino, D. L. Court, Enhanced levels of lambda Red-mediated recombinants in
358 mismatch repair mutants. *Proceedings of the National Academy of Sciences of the*
359 *United States of America* **100**, 15748-15753 (2003).
- 360 9. J. Germer, G. Becker, M. Metzner, R. Hengge-Aronis, Role of activator site position
361 and a distal UP-element half-site for sigma factor selectivity at a CRP/H-NS-activated

- 362 sigma(s)-dependent promoter in *Escherichia coli*. *Molecular microbiology* **41**, 705-716
363 (2001).
- 364 10. T. N. Huynh *et al.*, An HD-domain phosphodiesterase mediates cooperative hydrolysis
365 of c-di-AMP to affect bacterial growth and virulence. *Proceedings of the National*
366 *Academy of Sciences of the United States of America* **112**, E747-756 (2015).
- 367 11. M. Christen, B. Christen, M. Folcher, A. Schauerte, U. Jenal, Identification and
368 characterization of a cyclic di-GMP-specific phosphodiesterase and its allosteric control
369 by GTP. *The Journal of biological chemistry* **280**, 30829-30837 (2005).
- 370 12. J. Gundlach *et al.*, An essential poison: Synthesis and degradation of cyclic di-AMP in
371 *Bacillus subtilis*. *Journal of bacteriology* 10.1128/JB.00564-15 (2015).
- 372 13. D. J. Drexler, M. Muller, C. A. Rojas-Cordova, A. M. Bandera, G. Witte, Structural and
373 Biophysical Analysis of the Soluble DHH/DHHA1-Type Phosphodiesterase TM1595
374 from *Thermotoga maritima*. *Structure* **25**, 1887-1897 e1884 (2017).
- 375 14. K. Hayashi *et al.*, Highly accurate genome sequences of *Escherichia coli* K-12 strains
376 MG1655 and W3110. *Mol Syst Biol* **2**, 2006 0007 (2006).
- 377 15. S. Herbst *et al.*, Transmembrane redox control and proteolysis of PdeC, a novel type of
378 c-di-GMP phosphodiesterase. *The EMBO journal* **37** (2018).
- 379 16. M. S. Paget, L. Chamberlin, A. Atrih, S. J. Foster, M. J. Buttner, Evidence that the
380 extracytoplasmic function sigma factor sigmaE is required for normal cell wall structure
381 in *Streptomyces coelicolor* A3(2). *Journal of bacteriology* **181**, 204-211 (1999).
- 382 17. K. A. Datsenko, B. L. Wanner, One-step inactivation of chromosomal genes in
383 *Escherichia coli* K-12 using PCR products. *Proceedings of the National Academy of*
384 *Sciences of the United States of America* **97**, 6640-6645 (2000).
- 385 18. L. C. Thomason, J. A. Sawitzke, X. Li, N. Costantino, D. L. Court, Recombineering:
386 genetic engineering in bacteria using homologous recombination. *Curr Protoc Mol Biol*
387 **106**, 1 16 11-39 (2014).
- 388 19. G. Witte, S. Hartung, K. Buttner, K. P. Hopfner, Structural biochemistry of a bacterial
389 checkpoint protein reveals diadenylate cyclase activity regulated by DNA
390 recombination intermediates. *Mol Cell* **30**, 167-178 (2008).
- 391 20. S. Schlimpert *et al.*, Two dynamin-like proteins stabilize FtsZ rings during *Streptomyces*
392 sporulation. *Proceedings of the National Academy of Sciences of the United States of*
393 *America* **114**, E6176-E6183 (2017).
- 394 21. M. M. Al-Bassam, J. Haist, S. A. Neumann, S. Lindenberg, N. Tschowri, Expression
395 Patterns, Genomic Conservation and Input Into Developmental Regulation of the
396 GGDEF/EAL/HD-GYP Domain Proteins in *Streptomyces*. *Front Microbiol* **9**, 2524
397 (2018).
- 398 22. D. I. Svergun, C. Barberato, M. H. J. Koch, CRY SOL - a Program to Evaluate X-ray
399 Solution Scattering of Biological Macromolecules from Atomic Coordinates *J. Appl.*
400 *Cryst.* **28**, 768-773 (1995).
- 401